Business Description
Creative Medical Technology Holdings Inc
NAICS : 325412
SIC : 2834
Description
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.98 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.78 | |||||
| Beneish M-Score | -0.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -88 | |||||
| 3-Year FCF Growth Rate | 82.7 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.8 | |||||
| 9-Day RSI | 59.72 | |||||
| 14-Day RSI | 60.94 | |||||
| 6-1 Month Momentum % | -49.04 | |||||
| 12-1 Month Momentum % | -81.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 55.43 | |||||
| Quick Ratio | 55.39 | |||||
| Cash Ratio | 55.39 | |||||
| Days Inventory | 91.25 | |||||
| Days Sales Outstanding | 5.29 | |||||
| Days Payable | 2580.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -707.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.35 | |||||
| Operating Margin % | -3941.3 | |||||
| Net Margin % | -5654.35 | |||||
| ROE % | -60.65 | |||||
| ROA % | -55.71 | |||||
| ROIC % | -514.76 | |||||
| ROCE % | -41.98 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 0.09 | |||||
| PS Ratio | 30.58 | |||||
| PB Ratio | 0.33 | |||||
| Price-to-Tangible-Book | 0.34 | |||||
| EV-to-EBIT | -1.46 | |||||
| EV-to-EBITDA | -1.49 | |||||
| EV-to-Revenue | 57.24 | |||||
| EV-to-Forward-Revenue | 9.59 | |||||
| EV-to-FCF | -1.47 | |||||
| Price-to-Projected-FCF | 3.72 | |||||
| Price-to-Net-Current-Asset-Value | 0.34 | |||||
| Price-to-Net-Cash | 0.34 | |||||
| Earnings Yield (Greenblatt) % | -68.49 |
